"Skipping Surgery for HER2+ Breast Cancer: Which Patients?" - Roxanne Nelson, RN, BSN
Surgery is an integral part of a breast cancer treatment regimen, but with recent advances in neoadjuvant systemic therapy, there may be patients who could skip the operation, specifically, women with HER2+ breast cancer who achieve a pathologic complete response after NST may be candidates for clinical trials that will evaluate non-operative management, say researchers. Sarah Cate, MD, assistant professor of surgery at the Icahn School of Medicine at Mount Sinai said the idea of skipping surgery is an important issue and something patients ask about all the time. “They want to know why they still need surgery if there isn't any evidence of cancer after chemo."
— Sarah P. Cate, MD, Assistant Professor, Surgery, Icahn School of Medicine at Mount Sinai
Mount Sinai Health System Expands Care in Staten Island
Nov 04, 2024 View All Press Releases
The Tisch Cancer Institute Emphasizes Critical Role of BRCA Testing For All Genders
Oct 14, 2024 View All Press Releases